GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

GSK is still on course with its clinical trials programme for vaccination against RSV in older adults, the larger market opportunity, but falling behind Pfizer in maternal immunisation is a blow ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Teva Pharmaceutical Industries Ltd. ADR-0.95% $24.61B ...

时值呼吸道传染病高发的季节，中国疾控中心最新监测数据（2025年第2周）显示，本周急性呼吸道传染病疫情仍处于较高水平。其中，流感病毒是导致近期急性呼吸道传染病的主要病原体，目前仍处于季节性流行期，预计本月中下旬流感活动水平会逐步下降，不同省份间流感活 ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...